Switzerland may liberalize mail-order rules for non-prescription drugs by 2029, potentially intensifying price competition and benefiting online players like Redcare.
The competitive landscape for over-the-counter (OTC) medicines in Switzerland could undergo a significant transformation in the coming years. A potential relaxation of rules governing the mail-order delivery of non-prescription drugs is the catalyst, a move that stands to primarily benefit online pharmacies. Redcare Pharmacy is already strategically positioned within this evolving market.
Market analysis focusing on Swiss healthcare group Galenica points to an anticipated liberalization of mail-order regulations for OTC products, with a timeline extending to 2029. The current regulatory environment is seen as restrictive for online providers: Swiss consumers presently require a prescription to order OTC items from online pharmacies. This constraint limits price comparison and competitive pricing pressure.
The core of the potential change lies precisely here. Should this regulatory hurdle be removed, competition would likely intensify, driven more aggressively by price and digital reach. For traditional brick-and-mortar pharmacies, this represents a direct challenge to a key revenue segment.
Analysts point to the German market as a relevant comparison. There, online pharmacies such as those operated by Redcare already offer OTC products at discounts estimated between 20% and 25% compared to standard pharmacy prices. Applied to Switzerland, a deregulation could trigger a similar dynamic in pricing.
In such a scenario, which players would hold the advantage? The analysis suggests that providers with established e-commerce infrastructure and aggressive pricing strategies are poised to gain, while traditional pharmacies could face market share and revenue erosion.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
For Redcare, Switzerland is more than just a market to watch. The company operates a joint venture with its Swiss online pharmacy, in which Galenica holds a 49% stake. However, the analyst report highlights a complicating factor: the operational margins of this joint venture are currently below those of other divisions within Galenica.
While an opening of the OTC mail-order market could accelerate business growth, it may simultaneously increase margin pressure. This dual effect makes the potential outcome for both partners less clear-cut than it might initially appear.
Separate from these regulatory considerations, Redcare’s shares faced downward pressure in recent trading. The stock price stood at €62.25, reflecting a single-day decline of 4.30%. Over a seven-day period, the loss accumulated to approximately 10%. The critical factor moving forward will be the specificity and certainty of Switzerland’s regulatory path toward 2029. Only then could this potential rule change transition from a topic of discussion into a measurable growth driver for the business.
Fresh Redcare Pharmacy information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
